Market Overview

GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

Share:
Related GSK
Almost The Whole World In This ETF's Hands
Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares
Is Gilead Sciences A Bargain? (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the completion of the phase III programme of an investigational LAMA/LABA involving approximately 6,000 patients with chronic obstructive pulmonary disease.

See full press release

Posted-In: News

 

Related Articles (THRX + GSK)

View Comments and Join the Discussion!